CT-025 Impact of Stem Cell Source on Outcome of Allogeneic Stem Cell Transplantation in Pediatric Cancer

Abstract

Allogeneic hematopoietic stem cell transplantation is an established option of therapy for many malignant and non-malignant diseases which involve the hematopoietic and immune systems. The numbers of patients who are eligible for this procedure are continuously increasing due to the better supportive care and the developments in the use of alternative donors and stem cell sources. A retrospective study included 159 patients transplanted at bone marrow transplantation unit, children cancer hospital Egypt (CCHE) 57357. All patients with high risk hematological malignancy were considered eligible. Stem cell source obtained for these patients was either bone marrow (BM) or peripheral blood (PB). HLA matching was either matched related donor (MRD) or haploidentical transplant. Impact of stem cell source on the outcome of these patients was analyzed. BM was the most commonly used graft source in 92.5% of cases with OS of 81.9% and EFS of 70.9%. PB was only used in 7.5% with 50% OS and 33.3% EFS (P value =0.021). MRD was used in 86% of patients, while 10.1% received their allograft from haploidentical donors. At the end of the study 64.8% of the patients were alive, 34.6% died while only one patient lost follow up. With median duration of follow up of 64 months, the 3-year overall survival of the whole patients was 64% Conclusions: Bone marrow has a better survival outcome as a source of stem cell in allogeneic SCT than peripheral blood. However, it should be noted than PB SCT was used in Juvenile myelomonocytic leukemia patients which is known to have the worst outcome when transplanted.